Jourdan et al. [15] showed that the OS and recurrence-free survival rate in patients with CBF-AML with exon 8 or 17 mutations did not significantly differ from those in patients without KIT mutations, regardless of CBF-AML subtype, whereas Paschka et al. [39] reported that both exon 8 and 17 mutations, particularly exon 17, adversely affected the 5-year OS and relapse risk of inv(16) AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.